H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HUTCHMED (China) Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Total Assets
$1.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
19%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Total Assets
HK$24.9B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
18%
S
SSY Group Ltd
HKEX:2005
Total Assets
HK$12.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
9%
U
United Laboratories International Holdings Ltd
HKEX:3933
Total Assets
ÂĄ22.8B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
4%
Sino Biopharmaceutical Ltd
HKEX:1177
Total Assets
ÂĄ66.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
20%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Total Assets
HK$266.4B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
23.8B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Total Assets?
Total Assets
1.3B USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Total Assets amounts to 1.3B USD.

What is HUTCHMED (China) Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
19%

Over the last year, the Total Assets growth was -3%.

Back to Top